Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shampa De

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
AIDS (London, England)|December 20, 2015
Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b studyJan van Lunzen, Andrea Antinori, Calvin J Cohen, et al.
Antiviral Research|August 19, 2018
HCV phylogenetic signature and prevalence of pretreatment NS5A and NS5B NI-Resistance associated substitutions in HCV-Infected patients in Mainland ChinaLai Wei, Masao Omata, Young-Suk Lim, et al.
The Lancet. Gastroenterology & Hepatology|June 13, 2020
Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label studyEric Lawitz, Charles S Landis, Steven L Flamm, et al.
Annals of Hepatology|April 21, 2017
Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin PretransplantEric M Yoshida, Paul Kwo, Kosh Agarwal, et al.
Journal of Gastroenterology|September 12, 2018
Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trialTetsuo Takehara, Naoya Sakamoto, Shuhei Nishiguchi, et al.
Hepatology International|July 22, 2018
Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antiviralsNamiki Izumi, Tetsuo Takehara, Kazuaki Chayama, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
AIDS (London, England)|December 20, 2015
Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b studyJan van Lunzen, Andrea Antinori, Calvin J Cohen, et al.
Antiviral Research|August 19, 2018
HCV phylogenetic signature and prevalence of pretreatment NS5A and NS5B NI-Resistance associated substitutions in HCV-Infected patients in Mainland ChinaLai Wei, Masao Omata, Young-Suk Lim, et al.
The Lancet. Gastroenterology & Hepatology|June 13, 2020
Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label studyEric Lawitz, Charles S Landis, Steven L Flamm, et al.
Annals of Hepatology|April 21, 2017
Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin PretransplantEric M Yoshida, Paul Kwo, Kosh Agarwal, et al.
Journal of Gastroenterology|September 12, 2018
Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trialTetsuo Takehara, Naoya Sakamoto, Shuhei Nishiguchi, et al.
Hepatology International|July 22, 2018
Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antiviralsNamiki Izumi, Tetsuo Takehara, Kazuaki Chayama, et al.
Pageof 2